

1 **Dengue seroprevalence study during COVID-19 pandemic in Bali**

2 **Sri Masyeni^{1*}, Rois Muqsith Fatawy², AAAL Paramasatiari³, Ananda Maheraditya³, Ratna**
3 **Kartika Dewi³, NW Winianti³, Agus Santosa³, Marta Setiabudy³, Nyoman Trisna**
4 **Sumadewi⁴, Sianny Herawati⁴,**

5

6 ¹Department of Internal Medicine, Faculty of Medicine and Health Science, University of
7 Warmadewa, Jl. Terompong 24, Denpasar, Bali, Indonesia.

8 ²Infectious Disease and Immunology Research Center, Indonesia Medical Education and
9 Research Institute, Faculty of Medicine, Universitas Indonesia, Jl. Salemba 6, Jakarta, Indonesia.

10 ³Faculty of Medicine and Health Science, University of Warmadewa, Jl. Terompong 24,
11 Denpasar, Bali, Indonesia.

12 ⁴Faculty of Medicine, University of Udayana, Jl. Sudirman Denpasar, Bali, Indonesia.

13

14 **Corresponding author:**

15 masyeniputu@yahoo.com (SM)

16

17 **Abstract**

18 **Introduction:** Dengue infection poses significant public health problems in tropical and
19 subtropical regions all over the world. The clinical manifestation of dengue varies from
20 asymptomatic cases to severe dengue manifestation. The detection of clinical cases enables us to
21 measure the incidence of dengue infection, whereas serological surveys give insights into the
22 prevalence of infection. This study aimed to determine the dengue prevalence among healthy adult
23 patients in Bali.

24 **Method:** Cross-sectional seroprevalence surveys were performed from July 2020 to June 2021
25 among healthy and adult patients in Denpasar Bali. Blood samples were collected from 539
26 randomly selected samples from urban sites in Denpasar. IgG antibodies against DENV were
27 detected in serum using a commercial enzyme-linked immunosorbent assay (ELISA) kit.

28 **Results:** Overall, the positive dengue seroprevalence rate among 539 clinically healthy adult
29 patients was high (85.5%). The subject's median age was 34.1 (range between 18-86.1) years old.
30 Most participants in the study were younger than 40 years old (61.2%). The gender is dominated
31 by males (54.5%). The study found a significant association of dengue seropositivity among people
32 age more than 40 years old with healthy status ($p=0.005$ and $p<0.001$, respectively). Another
33 seroprevalence study reported a lower rate of dengue infection in children in Indonesia (69.4%).
34 The difference may be associated with less probability of Aedes bites among the children. The
35 study reflected the proportion of asymptomatic dengue that needs better assessment with a
36 serological test.

37 **Conclusion:** The current study highlighted a high prevalence of dengue seropositive with a
38 relatively dominant proportion of asymptomatic cases. The study guides the physicians to beware
39 of every dengue infection in tropical countries and prevents the spread of the disease.

40 **Keywords:** DENV IgG antibodies, seroprevalence, infection.

41

42 **Introduction**

43 Dengue has been considered the disease of the forthcoming, with alarming epidemiological patterns
44 for both human health and the global economy[1]. The prevalence of dengue virus (DENV)
45 infection has been predicted to cause 390 million new cases arising each year and approximately
46 96 million dengue hemorrhagic fever (DHF) cases leading to hospitalization each year[2]. Four
47 serotypes of DENV (DENV-1, -2, -3, -4) have spread rapidly within countries and across regions,
48 causing epidemics and severe dengue disease, hyperendemicity of multiple dengue virus serotypes
49 in tropical countries, and autochthonous transmission in Europe and the USA[3,4]. However,
50 dengue as well as other infections have been reported to have decreased during the pandemic[5,6].

51 The burden of dengue disease in many dengue-endemic countries including Indonesia remains
52 poorly enumerated since the current passive surveillance systems capture only a trivial fraction of
53 all dengue cases. Furthermore, it mostly depends on clinical diagnoses which exclude milder and
54 atypical disease presentations [2,7]. Dengue transmission in Indonesia including Bali has become
55 hyperendemic and a major public health problem. Dengue fever has spread throughout Indonesia
56 since the first dengue case was reported in Surabaya in 1968 [8]. All four dengue serotypes have
57 been reported from Indonesian regions such as Western Java, Surabaya, Bali, and Jambi. [3,9–13].
58 Dengue infection in Bali has become a recurring and significant public health issue. The study
59 objective is to assess the prevalence of dengue infection detected by Indirect IgG ELISA.

60

61 **Material and methods**

62 Cross-sectional seroprevalence surveys performed in July 2020 – June 2021 among healthy adults
63 and non-dengue patients in Denpasar Bali. Blood samples collected from each of 539 randomly
64 selected samples from urban sites in Denpasar. DENV IgG antibodies were checked in serum. A
65 blood sample of 3 mL venous blood was taken into clot activator tubes from each participant. Serum
66 was separated by centrifugation at 1300 ×g for 10 min, kept at +4 °C, and transported to the
67 laboratory of Universitas Warmadewa on the days for further processing.

68 DENV anti-IgG antibody detection in the collected sera was performed using a commercial
69 enzyme-linked immunosorbent assay (ELISA) (catalog numbers EI 266a-9601-1 G, Panbio,
70 Luebeck, Germany) following the manufacturer's instructions. The kit's specificity and sensitivity
71 are 0.988 (95% CI: 0.979–0.993) and 0.892 (95% CI: 0.879–0.903), respectively. Briefly, serum
72 samples diluted 1:101 were added to microplates and optical densities (OD) measured with a
73 microplate reader. Antibody values ≥ 20 relative units/mL were considered seropositive.

74

75 *Ethical considerations*

76 The study protocol was approved by the Institutional Review Board of the Faculty of Medicine,
77 Udayana University, Bali, Indonesia (Approval No: 485/UN.14.2/KEP/2020). All study
78 participants were enrolled after providing written informed consent.

79 *Statistical analysis*

80 The descriptive analysis was used to describe the seroprevalence of dengue by Indirect IgG ELISA.
81 The Chi-square test was used to analyze the association between the variables.

82

83 **Results**

84 The study found a high prevalence of dengue infection among the participant. The baseline
85 characteristics of the participants were listed in table 1. The results show the high prevalence of
86 seropositive dengue among the participants can be seen in table 2.

87

88 **Table 1** Baseline characteristics of the participants (N:539)

Variables	Frequency	Percentage (%)
Age		
Median (IQR)	34.1 (18-86.1)	
< 40 y.o	330	61.2
≥ 40 y.o	209	38.8
Gender		
Male	294	54.5
Female	245	45.5
Indirect IgG Dengue		
Negative	72	13.4
Equivocal	6	1.1

Positive	461	85.5
Participants status		
Healthy	373	69.2
Any illness	166	37.8
Diagnosis (N: 166)		
COVID-19	43	25.9
Febrile illness	33	19.9
Non febrile illness	90	54.2

89

90 **Table 2** Association between the variables

Variable	Indirect IgG ELISA				<i>p</i>	
	Positif		Negatif			
	N	%	N	%		
Age						
< 40 y.o	330	271	82.1	59	17.9	0.005
≥ 40 y.o	209	190	90.9	19	9.1	
Gender						
Male	294	252	85.7	42	14.3	0.893
Female	245	209	85.3	36	14.7	
Participants status						
Healthy	373	336	90.1	37	9.9	<0.001
Any illness	166	125	75.3	41	24.7	

91 **Abbreviations:** IgG, Immunoglobulin G; DENV, Dengue Virus; ELISA, enzyme-linked
 92 immunosorbent assay; DHF, dengue hemorrhagic fever

93

94 Discussion

95 The burden of dengue infection is not well documented in Indonesia, particularly among adult
 96 populations. The current dengue seroprevalence study conducted on adults in Bali reveals that
 97 people in tropical countries are at risk of dengue infection since the seroprevalence was found as
 98 high as 85.5%. Another seroprevalence study reports a lower rate of dengue infection in children
 99 in Indonesia (69.4%)[14]. The difference may associate with less probability of Aedes bite among

100 the children than in the adult population. This study result is in line with another study that report
101 the seroprevalence rate was high (91.5%) across all eight study sites. The reason is the study was
102 conducted on adults and children in urban and rural populations in Thailand [15]. Study in Dhaka
103 reports the seroprevalence as high as 80%[16]. Carabali et al. (2017) report the seroprevalence of
104 dengue infection is 61% and only 3.3% of the seropositive subject has a past dengue history [17].

105 The current study also found that participants aged more than 40 years old had a significantly higher
106 proportion of dengue seropositive than participants aged less than 40 ($p=0.005$). This finding may
107 be related to the risk of Aedes bites being higher than younger age in their life. This is in line with
108 another study report in Thailand, which found more than 98% of participants older than 25 years
109 were found to be dengue seropositive[18].

110 Since the result history of suspected dengue infection was previously reported in only 60% of the
111 participant, we predict that there was an asymptomatic dengue infection among the participant,
112 compare with the results of the Indirect IgG Dengue ELISA result. The study results reflect the
113 proportion of asymptomatic dengue that needs to assess with the serological study. Having this
114 high seroprevalence (85.5%), the population have higher chance to be infected by dengue multiple
115 times. Being exposed to this virus multiple times could increase the risk of severe disease [19,20].

116 An individual who is infected with a different dengue serotype for the second time may suffer
117 antibody-dependent enhancement of infection, which means that antibodies from the previous
118 infection serve to disseminate viral infection and increase viremia[19]. Therefore, the possibility of
119 having high hospitalized patients of dengue infections should be of concern of the public health
120 office in Bali.

121 The limitation of the study is the recall bias related to dengue infection history among the
122 participants. Since we were only using Indirect IgG ELISA, we were unable to distinguish between
123 primary and secondary infections. On the other hand, the IgG antibodies of dengue virus remain on

124 the body for more than 5 years after the infection and the infection from years ago maybe detected
125 on this study. Indeed, the cross-reactivity among the Flaviviruses infection needs to determine with
126 the PRNT study that is not final yet in this study.

127 **Conclusion**

128 The current study highlighted a high prevalence of dengue seropositive people with a relatively
129 high proportion of asymptomatic dengue cases. The study results enable to guide the physician of
130 the risk of more severe dengue in every dengue infection in tropical countries.

131

132 **Acknowledgments**

133 We would like to thank all the participants, nurses, and the research team in the Faculty of Medicine
134 and Health Sciences, Universitas Warmadewa for supporting this study.

135 **Authors contributions**

136 Conceptualization: SM; data curation: AAALP, AM, RKD; formal analysis: NWW, AS, NTS;
137 funding acquisition: SM; laboratory investigator: MS, SH; writing original draft: SM, RMF;
138 writing-review & editing MS, RMF.

139

140 **Funding**

141 This work was supported by Grant from Ministry of Research and Higher Education Technology
142 to SM.

143 **Disclosure**

144 The author reports no conflicts of interest in this work.

145 References

- 146 1. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. *Nature*
147 *Reviews Disease Primers*. 2016;2(1):16055.
- 148 2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global
149 distribution and burden of dengue. *Nature*. 2013 Apr;496(7446):504–7.
- 150 3. Masyeni S, Yohan B, Sasmono RT. Concurrent infections of dengue virus serotypes in
151 Bali, Indonesia. *BMC Research Notes*. 2019;12(1):129.
- 152 4. Guzman MG, Harris E. Dengue. *Lancet*. 2015 Jan;385(9966):453–65.
- 153 5. Prasertbun R, Mori H, Mahittikorn A, Siri S, Naito T. Pneumonia, influenza, and dengue
154 cases decreased after the COVID-19 pandemic in Thailand. *Tropical Medicine and Health*.
155 2022;50(1):27.
- 156 6. Surendran SN, Nagulan R, Sivabalakrishnan K, Arthiyan S, Tharsan A, Jayadas TTP, et
157 al. Reduced dengue incidence during the COVID-19 movement restrictions in Sri Lanka
158 from March 2020 to April 2021. *BMC Public Health*. 2022;22(1):388.
- 159 7. Gubler DJ. Dengue, Urbanization and Globalization: The Unholy Trinity of the 21st
160 Century. *Tropical Medicine and Health*. 2011;39(4SUPPLEMENT):S3–11.
- 161 8. Hotta S, Miyasaki K, Takehara M, Matsumoto Y, Ishihama Y, Tokuchi M, et al. Clinical
162 and laboratory examinations on a case of “hemorrhagic fever” found in Surabaya,
163 Indonesia, in 1968. *Kobe J Med Sci*. 1970;16(4):203–10.
- 164 9. Kosasih H, Alisjahbana B, Nurhayati, de Mast Q, Rudiman IF, Widjaja S, et al. The
165 Epidemiology, Virology and Clinical Findings of Dengue Virus Infections in a Cohort of
166 Indonesian Adults in Western Java. *PLOS Neglected Tropical Diseases*. 2016 Feb
167 12;10(2):e0004390.
- 168 10. Wardhani P, Aryati A, Yohan B, Trimarsanto H, Setianingsih TY, Puspitasari D, et al.
169 Clinical and virological characteristics of dengue in Surabaya, Indonesia. *PLOS ONE*.
170 2017 Jun 2;12(6):e0178443.
- 171 11. Masyeni S, Yohan B, Somia IKA, Myint KSA, Sasmono RT. Dengue infection in
172 international travellers visiting Bali, Indonesia. *Journal of Travel Medicine*. 2018 Jan
173 1;25(1):tay061.
- 174 12. Megawati D, Masyeni S, Yohan B, Lestarini A, Hayati RF, Meutiawati F, et al. Dengue in
175 Bali: Clinical characteristics and genetic diversity of circulating dengue viruses. *PLoS*
176 *Neglected Tropical Diseases*. 2017;11(5):1–15.
- 177 13. Haryanto S, Hayati RF, Yohan B, Sijabat L, Sihite IF, Fahri S, et al. The molecular and
178 clinical features of dengue during outbreak in Jambi, Indonesia in 2015. *Pathogens and*
179 *Global Health [Internet]*. 2016 Apr 2;110(3):119–29. Available from:
180 <https://doi.org/10.1080/20477724.2016.1184864>
- 181 14. Prayitno A, Taurel AF, Nealon J, Satari HI, Karyanti MR, Sekartini R, et al. Dengue
182 seroprevalence and force of primary infection in a representative population of urban
183 dwelling Indonesian children. *PLOS Neglected Tropical Diseases*. 2017 Jun
184 15;11(6):e0005621.
- 185 15. Doum D, Overgaard HJ, Mayxay M, Suttiprapa S, Saichua P, Ekalaksananan T, et al.
186 Dengue Seroprevalence and Seroconversion in Urban and Rural Populations in
187 Northeastern Thailand and Southern Laos. Vol. 17, *International Journal of Environmental*
188 *Research and Public Health* . 2020.
- 189 16. Dhar-Chowdhury P, Paul KK, Haque CE, Hossain S, Lindsay LR, Dibernardo A, et al.
190 Dengue seroprevalence, seroconversion and risk factors in Dhaka, Bangladesh. *PLOS*
191 *Neglected Tropical Diseases*. 2017 Mar 23;11(3):e0005475.
- 192 17. Carabali M, Lim JK, Velez DC, Trujillo A, Egurrola J, Lee KS, et al. Dengue virus
193 serological prevalence and seroconversion rates in children and adults in Medellin,

- 194 Colombia: implications for vaccine introduction. *International journal of infectious*
195 *diseases : IJID : official publication of the International Society for Infectious Diseases.*
196 2017 May;58:27–36.
- 197 18. Limkittikul K, Chanthavanich P, Lee KS, Lee JS, Chatchen S, Lim SK, et al. Dengue
198 virus seroprevalence study in Bangphae district, Ratchaburi, Thailand: A cohort study in
199 2012-2015. *PLOS Neglected Tropical Diseases.* 2022 Jan 4;16(1):e0010021.
- 200 19. Halstead SB. Neutralization and Antibody-Dependent Enhancement of Dengue Viruses.
201 *Advances in Virus Research.* 2003;60:421–67.
- 202 20. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-
203 dependent enhancement of severe dengue disease in humans. *Science.* 2017
204 Nov;358(6365):929–32.
- 205